Johns Hopkins Medicine: Experimental Type 1 Diabetes Drug Shelters Pancreas Cells From Immune System Attack
April 30, 2024
April 30, 2024
BALTIMORE, Maryland, April 30 (TNSres) -- Johns Hopkins Medicine issued the following news release:
Scientists at Johns Hopkins Medicine say that an experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the animals' lifespan.
The drug is unique, according to the researchers, because it targets insulin-making beta cells in the pancreas directly and is designed t . . .
Scientists at Johns Hopkins Medicine say that an experimental monoclonal antibody drug called mAb43 appears to prevent and reverse the onset of clinical type 1 diabetes in mice, and in some cases, to lengthen the animals' lifespan.
The drug is unique, according to the researchers, because it targets insulin-making beta cells in the pancreas directly and is designed t . . .